ABBOTT LABORATORIES (ABT)
Pharmaceutical Preparations · Pharmaceutical Preparations · NYSE
$112.69
+2.10%
Investingg Score
54.1 / 100
Hold
Business overview
- Operating margin stands at 18.2%.
- Free cash flow margin is reported at 16.7%.
- Market capitalization data is unavailable.
These profitability margins indicate solid operational efficiency and cash generation capabilities despite missing market cap figures.
Financial health
- Balance sheet pillar score is 57 out of 100.
- Risk pillar score registers at a high 90 out of 100.
- Gross margin is unavailable.
Together, these metrics point to a moderately stable balance sheet with favorable risk characteristics, though missing margin details introduce some uncertainty.
- Gross Margin
- Data unavailable
- Operating Margin
- 18.2%
- Current Ratio
- 1.6x
- Debt / Equity
- 0.19
- Free Cash Flow (TTM)
- $7.4B
- Interest Coverage
- Data unavailable
Valuation
- P/E ratio is unavailable.
- EV/EBITDA ratio is unavailable.
- P/S ratio is 0.
- FCF yield is unavailable.
The lack of standard valuation multiples limits direct assessment, leaving only a valuation pillar score of 55 to interpret.
- P/E (TTM)
- Data unavailable
- Forward P/E
- Data unavailable
- Price / Sales
- 0.0x
- EV / EBITDA
- Data unavailable
- FCF Yield
- Data unavailable
Key risks
- Sharp year-over-year contraction in earnings per share of -51.3%.
- Missing valuation metrics such as P/E ratio and FCF yield create valuation uncertainty.
- Data unavailable for gross margin and market capitalization limit complete financial evaluation.
Market cap $0 · data as of 2026-08-18
Get the full interactive report
Technicals, earnings history, news, bull/base/bear scenarios, Ask the Stock, and more — free to start.
Analyze ABT with Investingg AINot investment advice. Investingg AI summarizes public data and AI-generated analysis for informational purposes only.